Supply Chain
Long wait times, crowded waiting rooms, and frustrated staff are often symptoms of inefficient workflows driven by physical space constraints.…
A majority of healthcare leaders cite high drug costs as a major challenge for their organization, according to a new Premier survey.
The city of Rockford, Ill., filed a lawsuit April 6 against Mallinckrodt Pharmaceuticals over the price of its hormone drug, H.P Acthar, reports Business Insider.
Many drug companies supported Saturday's March for Science protest, despite President Donald Trump's growing scrutiny of the pharmaceutical industry, reports CNBC.
Here are the four latest drugs or medical devices approved by the Food and Drug Administration this week.
The Food and Drug Administration on Thursday gave market clearance to Cardiac Insight's wearable electrocardiogram sensor, Cardea Solo.
The Food and Drug Administration on Tuesday approved electroCore's gammaCore device to treat cluster headaches.
Valeant Pharmaceuticals' new treatment for plaque psoriasis will cost $3,500 a month, reports Reuters.
U.S. net prices for prescription drugs — the amount drugmakers receive after rebates from pharmacy benefit managers — increased 6 percent in 2016, according to a Credit Suisse report cited by Business Insider.
While utilization management policies help lower healthcare costs, they can hinder patient access to crucial cancer therapies, according to a policy statement from the American Society of Clinical Oncology.
The Food and Drug Administration approved Genentech's drug Lucentis to treat all forms of diabetic retinopathy — a complication of diabetes that leads to vision loss.